



# International Biotechnology Trust plc

---

## Investing in Biotechnology for a Healthier Future

---

Half Yearly Report | Six months ended 28 February 2023

WELCOME TO

# INTERNATIONAL BIOTECHNOLOGY TRUST PLC'S

HALF YEARLY REPORT FOR THE SIX MONTHS ENDED 28 February 2023



## WHO WE ARE


International Biotechnology Trust plc offers investors access to the fast-growing biotechnology sector through an actively managed, diversified portfolio.

Our award-winning Investment Managers at SV Health Managers LLP are scientifically, medically and financially experienced with over 75 years of experience between them. As well as investing in a wide-ranging portfolio of global quoted biotechnology stocks, we include a small proportion of otherwise inaccessible, carefully selected


unquoted investments which have the potential to deliver additional returns over the long-term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in our diversified portfolio of assets. The six key attributes of the Company are detailed below:




**Strong fundamentals**  
Driven by the strong fundamental demand and supply of the Biotechnology sector



**Diversified portfolio**  
Access to a broad spectrum of quoted and unquoted investments



**Growth and yield**  
Provides investors exposure to both growth and an attractive yield



**Active management**  
Bottom up stock selection with diversification overlay



**Expert team**  
Managed by a team of biotech experts with access to industry specialist key opinion leaders



**Innovation**  
Invested in some of the most innovative companies in the world, developing therapies to improve and save lives

28 February 2023

## FUND FACTS

FINANCIAL HIGHLIGHTS			
	(Unaudited) 28 February 2023	(Unaudited) 28 February 2022	(Audited) 31 August 2022
<b>Total equity/net asset value (NAV) (£'000)</b>	<b>295,496</b>	267,040	284,889
<b>NAV per share*</b>	<b>724.9p</b>	648.8p	697.2p
<b>Share price</b>	<b>690.0p</b>	636.0p	651.5p
<b>Share price discount*</b>	<b>(4.8)%</b>	(2.0)%	(6.6)%
<b>Gearing*</b>	<b>8.2%</b>	16.9%	14.0%
<b>Ongoing charges**</b>	<b>1.4%**</b>	1.4%**	1.3%**
<b>Ongoing charges including performance fee*</b>	<b>1.4%**</b>	1.4%**	1.5%**

\*Alternative Performance Measures (APMs). For detailed calculations on the discount/premium, gearing and ongoing charges, please refer to APMs on pages 29 and 30.

†Calculated in accordance with the Association of Investment Companies (the AIC) guidance. Based on total expenses excluding finance costs and performance fee and expressed as a percentage of average daily net assets. The ratio including performance fee has also been provided, in line with the AIC recommendations. Research costs under MiFID II borne by the Company are included in the ongoing charges calculation.

\*\*Includes Management fees paid to SV Health Managers LLP directly from investment in SV Health Investor's Fund VI (SV Fund VI) and SV Biotech Crossover Opportunities Fund (SV BCOF) (SV unquoted funds) of £428,000 (28 February 2022: £92,000; 31 August 2022: £392,000).

PERFORMANCE			
	(Unaudited) Six months ended 28 February 2023	(Unaudited) Six months ended 28 February 2022	(Audited) Year ended 31 August 2022
<b>Cumulative Total Return</b>			
<b>NAV per share total return*</b>	<b>6.1%</b>	-15.1%	-6.4%
<b>Share price total return*</b>	<b>8.0%</b>	-10.7%	-6.9%
<b>NASDAQ Biotechnology Index (NBI)</b>	<b>1.8%</b>	-23.0%	-13.8%
<b>FTSE All-Share Index</b>	<b>8.7%</b>	2.4%	1.0%

\*Alternative Performance Measures (APMs). For detailed calculations on the discount/premium, gearing and ongoing charges, please refer to APMs on pages 29 and 30.

Data for NBI and FTSE All-Share Index sourced from Bloomberg. All sterling adjusted and on a total return basis (with dividends reinvested).

PORTFOLIO OVERVIEW			
	28 February 2023	28 February 2022	31 August 2022
<b>Total number of portfolio companies*</b>	<b>74</b>	82	72
<b>Number of quoted holdings</b>	<b>65</b>	74	64
<b>Number of unquoted holdings**</b>	<b>9</b>	8	8
<b>NAV (£'m)</b>	<b>295.5</b>	267.0	284.9
<b>Quoted investments (£'m)</b>	<b>287.0</b>	284.2	285.5
<b>Unquoted investments (£'m)**</b>	<b>34.7</b>	28.2	28.0
<b>Net (debt)/cash (£'m)†</b>	<b>(24.2)</b>	(45.1)	(40.0)

\*Excluding unquoted companies fully written off (28 February 2023: 14; 28 February 2022: 11; 31 August 2022:15).

\*\*Includes SV Fund VI and SV BCOF as individual unquoted holdings. SV Fund VI has 18 companies in its portfolio, of which two are quoted as at 28 February 2023. SV BCOF has six companies in its portfolio, of which one is quoted as at 28 February 2023.

†Debt as at 28 February 2023 is a result of the Investment Managers' gearing strategy. Please refer to Glossary on pages 31 and 32 and APMs on pages 29 and 30 for more information.


## PORTFOLIO COMPOSITION

### AS AT 28 FEBRUARY 2023

#### NAV% by Size\*


- Mega cap > \$30bn
- Large cap = \$10-30bn
- Mid cap = \$2-10bn
- Small cap < \$2bn
- Unquoted funds
- Directly-held unquoted

\*Adjusted for cash/(debt) balance




#### NAV% by Development Stage

- Profitable
- Revenue growth
- Early-stage



#### NAV% by Therapeutic Area



\*Other includes unquoted funds

#### NAV% by Geography




82% US 16% Europe/UK 2% Rest of World

### AS AT 31 AUGUST 2022

#### NAV% by Size\*


- Mega cap > \$30bn
- Large cap = \$10-30bn
- Mid cap = \$2-10bn
- Small cap < \$2bn
- Unquoted funds
- Directly-held unquoted

\*Adjusted for cash/(debt) balance




#### NAV% by Development Stage

- Profitable
- Revenue growth
- Early-stage



#### NAV% by Therapeutic Area



\*Other includes unquoted funds

#### NAV% by Geography



86% US 11% Europe/UK 3% Rest of World

## TOP 10 QUOTED HOLDINGS

<p><b>Seagen</b></p> <p><b>10.0% of NAV</b> <b>Market cap of \$33.6bn</b></p> <p>A revenue growth biotechnology company with four launched products which treat various cancer indications. The company specialises in developing monoclonal antibody drug conjugates.</p>	<p><b>Amgen</b></p> <p><b>5.9% of NAV</b> <b>Market cap of \$123.7bn</b></p> <p>A large, profitable biotechnology company that develops and manufactures medicines for a broad range of diseases.</p>
<p><b>Harmony</b></p> <p><b>5.0% of NAV</b> <b>Market cap of \$2.6bn</b></p> <p>A profitable biotechnology company focusing on the treatment of rare neurological disorders of sleep-wake state. The company has a launched product, Wakix, indicated to treat narcolepsy.</p>	<p><b>Supernus</b></p> <p><b>4.4% of NAV</b> <b>Market cap of \$2.0bn</b></p> <p>A profitable, specialty pharmaceutical company with a portfolio of treatments to address neurological and psychological problems such as epilepsy and ADHD.</p>
<p><b>Alkermes</b></p> <p><b>4.4% of NAV</b> <b>Market cap of \$4.4bn</b></p> <p>A profitable specialty pharmaceutical company with many launched products. The company's primary growth driver is a recently launched product to treat adults with schizophrenia and bipolar disorder.</p>	<p><b>Uniqure</b></p> <p><b>4.3% of NAV</b> <b>Market cap of \$1.0bn</b></p> <p>A revenue growth biotechnology company with a newly launched gene therapy to treat haemophilia B patients. Its lead asset, Hemgenix, is partnered with major pharmaceutical company CSL Ltd.</p>
<p><b>Incyte</b></p> <p><b>4.1% of NAV</b> <b>Market cap of \$3.8bn</b></p> <p>A profitable biotechnology company with a key product, Ruxolitinib, approved for several rare hematological diseases and atopic dermatitis.</p>	<p><b>Intra-Cellular</b></p> <p><b>3.5% of NAV</b> <b>Market cap of \$4.6bn</b></p> <p>A revenue growth biotechnology company focused on the central nervous system. The company recently launched Caplyta for the treatment of schizophrenia and bipolar disorder.</p>
<p><b>Mirati</b></p> <p><b>3.1% of NAV</b> <b>Market cap of \$2.7bn</b></p> <p>A development stage oncology company focusing on small molecule drugs for acquired mutations, foremost the KRAS 12C prevalent in lung cancer.</p>	<p><b>Exelixis</b></p> <p><b>2.6% of NAV</b> <b>Market cap of \$5.5bn</b></p> <p>A profitable biotechnology company with a launched drug, Cabozantinib, indicated to treat renal and liver cancer.</p>

For full portfolio holdings, please refer to pages 26 to 28.

## CONTENTS

Chair's Statement.....	7
Fund Manager's Review .....	10
Environmental, Social and Governance Policy .....	14
Interim Management Report and Directors' Responsibilities Statement .....	17
Statement of Comprehensive Income.....	18
Statement of Changes in Equity.....	19
Balance Sheet .....	20
Cash Flow Statement.....	21
Notes to the Financial Statements.....	22
Quoted Investments .....	26
Unquoted Investments.....	28
Alternative Performance Measures (APMs).....	29
Glossary of Terms.....	31
Company Summary and Shareholder Information.....	33
Directors and Advisers .....	34



International  
Biotechnology  
Trust plc

Further information on the Company  
may be found on the internet at:

[www.ibtplc.com](http://www.ibtplc.com)



28 February 2023

## CHAIR'S STATEMENT

I am pleased to report that the Fund Manager has again produced a strong set of results in the first six months ended 28 February 2023. This is my first report since taking over as Chair in December, and I would like to record my thanks to Jim Horsburgh for his tenure. The Company's share price returned 8.0% over the six month period, well ahead of the Nasdaq Biotechnology Index (NBI), which had a total return of 1.8%. The Company's Net Asset Value (NAV) total return over the period was 6.1%. Over three years to the end of February 2023, the total share price return was 43.2%, versus 22.6% for the NBI, and the Company's share price was also ahead over five years with a total return of 43.8% versus 41.2% for the NBI. All figures are on a sterling adjusted total return basis, with dividends reinvested.

These returns are all the more impressive given the continued upheaval in global equity markets. Markets worldwide are grappling with high levels of inflation and rising interest rates, the ongoing conflict in Ukraine and increasing geopolitical tension between the US and China. The abandonment of the Zero COVID-19 policy in China led to a recovery in global, and particularly, Asian markets during the period, whilst political gyrations in the UK in September led to a fall in the FTSE, followed by a recovery in the final months of 2022. The frothy valuations seen in the biotechnology sector during the pandemic have now been largely unwound, which has led to a more fertile environment for M&A activity. Both the quoted portfolio and the unquoted portfolio benefitted from being invested in takeover targets during the first six months of the Company's financial year.

### QUOTED PORTFOLIO

Our joint lead Investment Managers, Ailsa Craig and Marek Poszepczynski have continued to focus on identifying revenue generating innovative biotech opportunities with significant success. During the six months ended 28 February 2023, the NAV per share of the quoted portfolio returned 5.8%, substantially outperforming the reference benchmark of the NBI which returned 1.8%.

During the period under review, the portfolio benefitted from having positions in three quoted companies which were the subject of takeover bids. Of particular note, was the announcement in December 2022 of the acquisition of Horizon Therapeutics by Amgen, which has not yet completed and is subject to regulatory approval. Amgen agreed to pay a premium of 47.9% above the last closing price of Horizon Therapeutics prior to the announcement that the company was the subject of a takeover bid on 29 November 2022. At the time of the announcement Horizon was the largest position in the quoted portfolio representing 13.5% of IBT's NAV.



KATE CORNISH-BOWDEN | Chair

## CHAIR'S STATEMENT | continued

The rising interest rate environment continues to have an impact on the financing and valuation of smaller early stage biotech companies. The Investment Managers' decision to overweight exposure towards larger biotech companies with proven therapeutics which are already generating revenues has, thus far, been vindicated.

### UNQUOTED PORTFOLIO

The Investment Managers of the unquoted portfolio, Kate Bingham and Houman Ashrafiyan have also achieved strong performance for investors over the period. As at 28 February 2023, the unquoted portfolio comprised 11.8% of the Company's NAV. The portfolio currently includes two unquoted funds, SV Fund VI and SV BCOF as well as a small number of directly held unquoted companies, most of which have been exited with contingent milestones.

#### SV Fund VI

SV Fund VI, which represents 5.8% of IBT's NAV, has performed well, delivering a currency adjusted internal rate of return (IRR) of 20.5% per annum since the Company's first investment in the fund in 2016. The Fund, which includes a range of early-stage biotech, medical device and healthcare services companies, is now a mature portfolio with 83% of the capital committed drawn down. During the six months ended 28 February 2023, SV Fund VI made one distribution of \$1.8m (£1.6m) and one capital call of \$0.9m (£0.8m).

#### SV BCOF

During the period under review, IBT increased its commitment to SV BCOF, the newer fund which invests in later stage and/or pre-IPO opportunities. SV BCOF now represents 4.2% of IBT's NAV. The \$30m commitment is only 27% drawn down, but the fund has had a notable early success with a £5.5m uplift in the period. In February 2023 Nimbus Therapeutics, an early BCOF investment, sold its TYK2 Inhibitor, which had demonstrated promising Phase 2 results in psoriasis, to Takeda for \$4bn in upfront cash, and up to \$2bn in commercial milestone payments.

### PERFORMANCE FEE

Thanks to outperformance in both the quoted and unquoted portfolios, a performance fee of £199,000 has been accrued in the accounts for the six months to 28 February 2023. The quoted portfolio achieved more than 10% relative performance above the NBI benchmark

plus a 0.5% hurdle rate which has led to an accrual of £150,000 in performance fees. The accrued performance fee of £49,000 on the unquoted portfolio is due to net realised gains during the period.

### DIVIDENDS

The Company's approved dividend policy (last approved at the 2022 AGM) is to make dividend payments equivalent to 4% of the Company's NAV, as at the last day of the preceding financial year ending 31 August through two equal semi-annual distributions. The first dividend for the year of 14 pence per share was paid on 27 January 2023. The Board intends to make the declaration of the second dividend for the year in accordance with the above policy in July for payment in August 2023.

### DISCOUNT AND PREMIUM MANAGEMENT

The Board keeps the Company's share price discount to NAV under close review and is committed to buying back its shares to help manage the discount. Similarly, the Board is keen to grow the Company and will issue shares when the share price is trading at a premium to NAV. During the six months under review, 98,180 shares were bought back to be held in Treasury. The share price discount to NAV, which was 6.6% at 31 August 2022 had narrowed to 4.8% at 28 February 2023.

### ESG

The Board recognises the importance that investors place on their funds being invested in responsible companies which generate sustainable returns. The companies in which IBT invests have an important social impact through extending and enhancing human life. Our Investment Managers seek to identify companies which are developing innovative treatments for diseases where there is a high unmet need, and where progress is not only profitable, but life changing for patients.

In accordance with our ESG policy, the Investment Managers incorporate an ESG screening process in the investment process. Data provided by Morningstar's Sustainalytics is used to measure the environmental and social impact and the quality of their governance in key portfolio holdings. The results of this screen are outlined on page 15 of this report.



## CHAIR'S STATEMENT | continued

### BOARD SUCCESSION

Following Jim Horsburgh's retirement from the Board, we engaged an independent search consultant to help us identify a new director. I am delighted to welcome Gillian Elcock, who joined the Board at the beginning of February 2023. Gillian was the founder and Managing Director of Denny Ellison, an independent investment research company, and is a highly experienced equity research analyst. Gillian is also a member of the Board of the CFA UK. Gillian will stand for election at the Company's AGM in December.

### CHANGE OF MANAGER

As announced on 13 February 2023, the Company's AIFM and Manager, SV Health has decided to focus on its venture capital business and has served notice of termination to IBT plc. Whilst this was an unexpected development, the Board understands SV's decision and is pleased that the Investment Managers will continue to focus on delivering results for shareholders during the transition period.

In order to ensure that shareholders views are uppermost in our minds as we deliberate on the future for IBT, the Board engaged with many of our key shareholders following the announcement. We have listened to our shareholders and sought to understand their perceptions of IBT's strengths and the key reasons why they have chosen to invest. We have used this comprehensive feedback to inform our decisions during the independent process of selecting a new manager for IBT. I am pleased to report that we received many expressions of interest in managing the Company's assets. Together with our professional advisers, we narrowed this field down to a short list of candidates before sending them request for proposals. We then selected six institutions to present to the Board. At the time of writing, we are in the process of reviewing the presentations we have received. Unfortunately, we are currently unable to disclose further details during these confidential negotiations. We are determined to minimise the period of uncertainty and expect to be able to release more information in the near future. We would like to thank shareholders for their support and patience.

### OUTLOOK

Since the half year end in February, the risk of contagion following the demise of Silicon Valley Bank and Signature Bank in the US, and Credit Suisse in Europe, has sent shivers through the market. Nevertheless, the Board believes that the biotechnology sector offers a very compelling long term

investment opportunity. Over the 20 years from the end of 2002 to the end of 2022 the NBI has produced an average return of 13.3% per annum versus 11.4% for the S&P 500.

The aging global population will continue to ensure strong demand for therapeutics to treat disease and enhance quality of life. We are living through a period of great innovation in medical science, including exciting advances in cell based and gene therapies, which have the potential to change outcomes for patients suffering from diseases such as cancer and dementia. The renewed focus on drug development following the global pandemic has highlighted the potential for faster, more personalised clinical trials which should reduce the risks of late stage failure.

Cash rich, large pharmaceutical companies needing to replenish their pipelines are increasingly looking to the smaller revenue generating innovative companies in which IBT invests. We share our Investment Managers' enthusiasm that the current more realistic valuations and the prospects for increased corporate activity in the biotech sector represent an excellent opportunity for IBT shareholders.

**KATE CORNISH-BOWDEN | Chair**

2 May 2023

## FUND MANAGER'S REVIEW



**Ailsa Craig**  
*Lead Investment Manager*

Ailsa joined SV Health in 2006 and is joint lead Investment Manager of the Company. Ailsa has a BSc (Hons) in Biology from the University of Manchester. She was awarded the IMC in 2002 and a Securities Institute Diploma in 2007.



**Marek Poszepczynski**  
*Lead Investment Manager*

Marek joined SV Health in 2014 and is joint lead Investment Manager of the Company. Marek has an MSc in Biochemistry and an MSc in Business Management from the Royal Institute of Technology, Stockholm.



**Kate Bingham**  
*Managing Partner SV*

Kate joined SV Health in 1991 and manages the Company's unquoted investments. She has a first class degree in Biochemistry from Oxford University, and graduated from Harvard Business School with an MBA.



**Houman Ashrafian**  
*Managing Partner SV*

Houman joined SV Health in 2016 and manages the Company's unquoted investments. Houman is currently Head of Experimental Therapeutics at the University of Oxford and an Honorary Consultant Cardiologist, John Radcliffe Hospital, Oxford.

### SUMMARY

In the six months to 28 February 2023, the NAV per share returned 6.1% and the share price returned 8.0%. The Company's benchmark, the NASDAQ Biotechnology Index, returned 1.8%. All figures are on a sterling adjusted total return basis, with dividends reinvested.

By subsector, 74% of the portfolio was invested in therapeutics, 13% in speciality pharmaceuticals and 4% in life sciences, tools, and diagnostics. 9% of the Company was invested in venture funds.

The Company's three largest therapeutic areas were oncology 36%, rare diseases 16%, and diseases of the central nervous system 15%.

At the end of the period the Company's gearing position was 8.2% and the Company's discount had narrowed from 6.6% to 4.8%.

### QUOTED PORTFOLIO

For the six-month period ended 28 February 2023, the NAV of the quoted portfolio returned 5.8%, versus 1.8% for the NASDAQ Biotechnology Index (gross of management and performance fees). All figures are on a sterling adjusted total return basis, with dividends reinvested.

### Market Backdrop

During the period under review, global macro-economic conditions have continued to be uncertain. Interest rates across the world have risen and investors have been cautious about investing into areas deemed to be risky.

Continued inflationary pressure has caused monetary policy makers to increase interest rates faster than anticipated. The rise in interest rates led to renewed popularity of debt instruments. Following record inflows into equities during the pandemic, the third quarter of 2022 saw record outflows from UK equities following the brief tenure of Liz Truss as Prime Minister.

## FUND MANAGER'S REVIEW | continued

### BEST PERFORMING INVESTMENTS

	Contributors to NAV (£'m)
Horizon Therapeutics	16.8
Gilead Sciences	3.0
Biogen Inc	3.0

The biotech sector has seen a divergence in performance depending on the characteristics of the specific biotech company. Smaller early stage companies have struggled to keep their valuations compared to their larger, more diversified peers. While innovation in these smaller companies has been exciting, investors have held off from backing them due to concerns over financing costs. In the last quarter of 2022 investors, fearing that the rising valuations seen in technology companies were unsustainable, rotated their focus into the largest biotech companies. In turn, those mega cap biotech names which are usually considered to be slow growth in nature, experienced an unexpected boost to performance. At the start of 2023, following a correction in the global mega-cap technology companies, that money retreated back into technology, causing a retraction in the 'safe haven' mega cap biotech names. Meanwhile the performance of the mid-tier biotech companies which have products that have been approved and are on the market but have not yet turned profitable, have been relatively robust and several of them have benefitted from the acquisition appetite of the cash-rich, large biopharma companies.

The Nasdaq Biotech Index (NBI) outperformed the S&P 500 over the period by 4.5% while the equal weighted S&P Biotech ETF (XBI) underperformed by 6.7% reflecting the relatively poor performance of smaller cap biotech companies against the sector as a whole.

### Mergers and acquisitions (M&A)

After a delay in M&A discussions driven partly by lockdowns in 2020 and overheated valuations in 2021, 2022 saw a return to a normalised deal flow. M&A is a hallmark of the healthcare ecosystem and in the period under review the company benefitted from three acquisitions of its quoted portfolio companies and a further one of its unquoted portfolio companies.

In December 2022, Amgen announced its intention to acquire portfolio company Horizon, a revenue growth stage company with a treatment for Thyroid Eye Disease. The deal was worth \$28bn which represented a premium of 48% to the share price.

### WORST PERFORMING INVESTMENTS

	Detractors from NAV (£'m)
Vera Therapeutics	-3.7
KalVista Pharmaceuticals	-3.1
Novavax Inc	-2.8

At the time of the announcement the Company had a position of 13.5% of NAV. This deal is not yet completed and is subject to regulatory approval.

In January 2023, Ipsen announced that it would acquire portfolio holding Albireo, a revenue growth stage company with an approved treatment for a rare liver disease. The deal was worth \$952m which represented a premium of 104% to the share price. At the time of the announcement the Company had a position of 0.23% of NAV.

Also in January 2023, Sun Pharma announced its intention to acquire Concert Pharmaceuticals. Concert Pharmaceuticals is a development stage company with an oral treatment for alopecia areata in late stage clinical trials. The deal was worth \$580m which represented a premium of 33% to the share price. At the time of the announcement the Company had a position of 0.33% of NAV.

Following the end of the period under review, on 13 March 2023, Pfizer announced that it had entered an agreement to acquire portfolio holding Seagen for \$43bn which represented a premium of 32.7% to the share price. At the time of the announcement, the Company had a position of 10.2% of NAV.

### Positive contributors to the NAV

Amgen announced its intention to acquire Horizon Therapeutics for \$28bn in December 2022. The company is focused on rare diseases, where Tepezza for thyroid eye disease (TED), the only approved drug to treat the disease, is the largest product. TED is a condition which results in a build up of fat tissue behind the eyes. The symptoms can cause double vision and bulging eyes. Despite the logistical complications arising from the COVID-19 pandemic at the time, the Tepezza launch was the most successful rare disease product launch of all time.

In the period under review, Gilead shares benefitted from the company's HIV and cell therapy franchises that reported stronger sales than expected. Also in the wake of general market turbulence in 2022, larger biopharma companies

## FUND MANAGER'S REVIEW | continued

including Gilead performed well as a group in the autumn when money flowed out of large cap technology stocks into the perceived 'safer haven' biopharma companies. Biogen, and partner Japanese pharmaceutical company Eisai, reported positive results for their Alzheimer's disease candidate lecanemab. The CLARITY-AD phase 3 trial hit its primary and key secondary endpoints. This large clinical trial compared lecanemab, an antibody that targets and eliminates amyloid-beta plaques, against placebo. The drug was found to reduce cognitive decline by 27% compared to placebo. Following on from this, lecanemab received approval from the Food & Drug Administration in January 2023 and was subsequently launched under the brand name 'leqembi'.

### Negative detractors to NAV

Vera Therapeutics reported phase two data in early January 2023 for its drug atacecept for immunoglobulin A nephropathy (IgAN), an autoimmune disease which attacks the kidneys. Atacecept has a dual APRIL/BLYS inhibition aiming to reduce the level of proteinuria in patients. Successfully reducing proteinuria is considered to be linked to longer term improvement of kidney function. The trial succeeded and showed a 30% reduction in proteinuria levels at nine months; however, investors had hoped for a greater reduction causing a sell-off in the shares.

KalVista announced it would be discontinuing a clinical trial investigating a prophylactic treatment for Hereditary Angioedema, a disorder characterised by recurrent episodes of severe swelling. KVD824 was in mid stage clinical trials for the rare condition and unfortunately was stopped due to unanticipated safety signals in some patients. The management therefore took the decision to terminate the programme.

Novavax successfully developed a vaccine for COVID-19 called Nuvaxovid which was approved for use in July of 2022. However, due to a litany of setbacks, including manufacturing issues, and being third to market after Moderna and Pfizer/BioNTech, the company failed to generate material sales.

### UNQUOTED PORTFOLIO

The Company's unquoted portfolio continues to perform well in its objective to give investors exposure to differentiated returns from quoted markets and access to innovative early stage companies. As at 28 February 2023, it comprised 11.8% of the Company's Net Asset Value (NAV) which is in line with the Company's strategy of maintaining its exposure to unquoted companies within 5-15% of total NAV.

The portfolio currently comprises investment in two unquoted funds, SV Fund VI and SV BCOF as well as a small number of directly held unquoted companies, most of which have exited with contingent milestones.

SV Fund VI is the Company's most significant unquoted investment and has performed well delivering a currency adjusted internal rate of return (IRR) of 20.5% per annum since the date of the Company's first investment in the fund in 2016. During the six months ended 28 February 2023, SV Fund VI made one distribution of \$1.8m (£1.6m) and one capital call of \$0.9m (£0.8m). The draw down to date on the commitment of \$30.0m is \$24.9m, which represents 83.1% of the total committed capital.

SV BCOF focuses on later stage and/or pre-IPO opportunities and invests in clinical and near clinical stage biotech companies in the UK, EU and US that have the potential to deliver excellent investor returns and address significant unmet medical needs in patients.

### SUMMARY OF UNQUOTED INVESTMENTS

	As at 28 February 2023			As at 31 August 2022		
	Fair value (£'m)	% of NAV	No. of investments	Fair value (£'m)	% of NAV	No. of investments
Unquoted funds	29.3	10.0%	24*	22.4	7.8%	24*
Exited with contingent milestones	5.0	1.7%	5	5.3	1.8%	5
Directly-held unquoted	0.4	0.1%	2	0.3	0.1%	1
<b>Total unquoted</b>	<b>34.7</b>	<b>11.8%</b>	<b>31</b>	<b>28.0</b>	<b>9.7%</b>	<b>30</b>

\* The number of investments within unquoted funds represents the number of investments into underlying individual portfolio companies. Three of these companies were quoted as at 28 February 2023.

28 February 2023

## FUND MANAGER'S REVIEW | continued

During the period, the Company committed a further \$5m (£4.2m), which raised its total commitment to \$30m. Since December 2021, \$8.3m of this capital has been invested. The fund has performed well due to one of its investments, Nimbus Therapeutics, being the subject of an acquisition. In February 2023, Takeda acquired Nimbus Lakshmi Inc, a wholly-owned subsidiary of Nimbus and its TYK2 inhibitor (NDI-034858) for \$4bn in upfront cash, and up to \$2bn in commercial milestone payments.

A fair value uplift of £5.5m was applied to the Company's investment in the fund, primarily as a result of the above Nimbus transaction.

### OUTLOOK

The fundamentals underpinning the biotech industry are ever more compelling. On the demand side, the global population continues to be more heavily weighted towards the over 60s which is driving demand for medicines. Further, a growing middle class in developing markets is demanding better access to healthcare which is increasing the global take up of new drugs. The biotech industry is keeping up with this demand through an accelerating pace of innovation and an evolving regulatory backdrop that is enabling drugs to reach the market in a more efficient manner.

The 2023 to 2028 period will see an increase in the number of treatments reaching their patent expiry dates. While the prevalence of less easy to replicate biologics will mean that copycat therapies are generally slower to take hold, there is pressure on the big pharmaceutical companies to plug

the impending revenue gaps in their product pipelines with new treatments.


The Investment Managers believe that big pharmaceutical companies, especially those with sound balance sheets stemming from COVID-19 vaccine and treatments sales, will be looking to deploy their cash and build their drug pipelines. Rather than focussing on early-stage biotech, the Investment Managers expect them to target de-risked companies with a shorter time horizon to profitability such as the 'revenue growth' names that already were the subject of acquisitions in the six months to February 2023.

With macro-economic uncertainty continuing and questions over access to affordable, reliable financing, the Investment Managers expect to continue to tilt the portfolio in favour of revenue growth and large cap biotech companies with carefully selected, well financed smaller cap names addressing the highest unmet needs making up the remainder of the portfolio.

Catalysts for 2023 are likely to include positive clinical readouts, good product launches, a steady flow of M&A deals and a reignition of biotech sector IPOs. Together, these could underpin investor interest in the sector and boost returns into the future. The Company is well positioned to benefit from these situations as they occur.

### SV HEALTH MANAGERS LLP

2 May 2023



## ENVIRONMENTAL, SOCIAL AND GOVERNANCE POLICY

The Company outlined its Environmental, Social and Governance (ESG) policy in its Annual Report for the year ended August 2021.

Its policy was adopted in October 2021, and since amended in February 2023, in conjunction with IBT's Fund Manager, SV Health Investors, and aims to integrate consideration for ESG factors into the investment process, governance and choice of suppliers for IBT and to exert influence on portfolio companies and suppliers to consider ESG factors in their respective activities. IBT's Board also considers ESG factors in its choice of suppliers.

All of IBT's investments and activities are aligned with UN Sustainable Development Goal number 3: 'Good Health and Well-being. Ensure healthy lives and promote well-being for all at all ages.' as well as six other goals. IBT is dedicated to investing in tomorrow's healthcare breakthroughs. IBT has invested in scientific development, medical innovation, and technologies across a wide spectrum of diseases with particular focus on areas of high unmet medical need. IBT also adheres to all six UN Principles for Responsible Investment and supports all the Ten Principles of the UN Global Compact.

### ESG REPORT

The Company has been delivering financial value to shareholders since 1994 whilst simultaneously creating a positive social impact by investing in companies that develop innovative treatments for patients suffering with unmet medical needs. The products developed by the companies we invest in can radically change the way diseases are treated, bringing positive impact to patients and healthcare systems globally.

IBT's investment approach in relation to ESG is based on three pillars:

1. Thorough ESG diligence and investing for impact;
2. Meaningful engagement with portfolio companies; and
3. Reporting to shareholders.

The Board considers that focussing on the ESG compliance of its investments and engaging with the management of key portfolio companies has the potential to bring about positive change in its investment universe. In particular, IBT believes its potential to generate the greatest impact will generally be on its top ten quoted holdings and its private holdings where IBT's larger investment size gives it greater influence.

The Board notes that ESG and sustainability concerns have become key considerations for many of its investors. The Board believes that through IBT's focus on ESG as an investor, it can help maximise its portfolio companies' positive impact whilst generating attractive investor returns.


In its Annual Report for the year ended 31 August 2022, IBT outlined the difficulties it had experienced in gathering meaningful data relating to the ESG compliance or otherwise of its top ten quoted holdings. As a result of that, a new policy has been designed which has been published on IBT's website at <https://ibtplc.com/esg-policy>.

The key difference in the policy is that IBT has now subscribed to the services of an external ESG monitoring agency, Sustainalytics which is part of Morningstar's platform, rather than using its bespoke ESG survey for its quoted portfolio. The decision to make this change was made after experiencing resistance from quoted portfolio companies to completing a bespoke ESG survey from a minority shareholder like IBT. This reflected the increasing pressure on companies from investors to give ESG information which in turn should lead to greater ESG awareness at portfolio companies. As a result of this pressure, companies are moving away from individual responses and are instead directing investors to their public ESG policies which makes meaningful comparisons of companies difficult.

Going forward, IBT intends to use the data gathered by Sustainalytics to monitor the compliance of its quoted portfolio with an accepted set of ESG standards. The benefit of this service means that IBT has access to a detailed set of ESG data on the majority of the quoted biotech universe which not only facilitates ESG reporting and enables comparisons to benchmarks beyond IBT's own portfolio, but also enables the incorporation of ESG screening into its portfolio management process. In addition, the access to this data means that IBT's Fund Managers can more readily engage with portfolio companies in respect to areas in which Sustainalytics considers them to fall short of their peers. IBT continues to commit to screening and reporting on the ESG compliance of its top ten quoted portfolio companies in aggregate on a semi-annual basis to coincide with the annual and interim period ends.

IBT's screening of the biotech companies in its unquoted portfolio will take place annually as before and will continue to depend on those companies completing SV's bespoke ESG screening questionnaire. This was reported on in the Annual Report for the year ended 31 August 2022. Of note, however, is that in October 2022, we are pleased to report

ENVIRONMENTAL, SOCIAL AND GOVERNANCE POLICY | continued



that Sustainalytics ranked one of the companies held in SV BCOF as having the lowest ESG Risk rating in the industry.

IBT continues to request its suppliers to provide ESG policies annually and seven of its suppliers have agreed to have links to their policies displayed on IBT's website.

Sustainalytics ranks the pharmaceutical and biotech industries in aggregate as relatively high risk in comparison to other industries. This is mainly driven by a combination of poor Quality and Safety scores (relating to drugs in clinical trials being found to be inefficacious or toxic), Business Ethics issues relating to drug pricing and availability and "Weak" management scores, relating, in the main, to poor disclosure or perceived failure to adequately mitigate the risks inherent in the industry. Arguably the Quality and Safety issues and Business Ethics issues are part and parcel of drug development and difficult for companies to avoid. Against that backdrop, it is unsurprising that Sustainalytics rates over 55% of companies as having Severe (14%) or High (42%) ESG Risk, with only 8% having Low ESG Risk.


In respect of the six months ended February 2023, we are pleased to report that 70% of IBT's top ten quoted holdings were rated with a Medium ESG Risk Score compared with 36% of the industry as a whole. Three of the top ten quoted companies were categorised as High ESG Risk with the highest risk of these falling in the 67<sup>th</sup> percentile of biotech companies screened by Sustainalytics and the others between the 20<sup>th</sup> and 40<sup>th</sup> percentile. None of IBT's top ten quoted companies were rated in the Severe category of ESG Risk. On a positive note, all three of the High ESG Risk companies in the top ten quoted companies are shown to be on a positive trajectory in comparison to their previous Sustainalytics screening. One of the three companies categorised as High ESG Risk has been the subject of recent active engagement by IBT's Investment Managers and we are pleased to see an improvement in its ranking. IBT's Investment Managers have closely examined the background behind the current ESG rankings of those companies categorised as High ESG Risk and established that the majority of the issues that have contributed to their High ESG Risk rating results from lack of disclosure

## ENVIRONMENTAL, SOCIAL AND GOVERNANCE POLICY | continued

rather than from any specific avoidable activity deemed to be counter to ESG principles. IBT's Investment Managers will engage with these companies over the coming months to ensure that the current disclosure is not concealing anything of concern, and to encourage them to adhere to best practice on disclosure.

IBT's Investment Managers look forward to having better access to ESG data on their portfolio through this new

relationship with Sustainalytics and using it as the basis for meaningful engagement on ESG matters with portfolio companies going forward as well as highlighting any areas of concern. IBT continues to negatively screen companies which would exclude from potential investment any companies which engage in certain unsavoury practices, such as price gouging, involvement in the US opioid scandal, "me-too" drugs lacking innovation and anything that leads to negative effects on public health or wellbeing.





28 February 2023

# INTERIM MANAGEMENT REPORT AND DIRECTORS' RESPONSIBILITIES STATEMENT

## INTERIM MANAGEMENT REPORT

The important events that have occurred during the period under review, the key factors influencing the financial statements and the principal risks and uncertainties for the remaining six months of the financial year are set out in the Chair's Statement on pages 7 to 9 and the Fund Manager's Review on pages 10 to 13.

The principal and emerging risks facing the Company are substantially unchanged since the date of the Annual Report and Accounts for the year ended 31 August 2022 and continue to be as set out in that report on pages 25 to 26. As detailed in the Chair's Statement on page 9, the Manager, SV Health has served notice of termination to IBT. The Board is working closely with its advisers to manage the risks associated with selection of, and transition to, a new Manager.

Risks faced by the Company include, but are not limited to, strategic/performance risk, political risk, investment related risks, operational and service provider risks and tax, legal and regulatory risks.

## DIRECTORS' RESPONSIBILITIES STATEMENT

In respect of the Interim Report for the six months ended 28 February 2023, we confirm that, to the best of our knowledge:

- the condensed set of Financial Statements contained within have been prepared in accordance with IAS 34 *Interim Financial Reporting* and give a true and fair view of the assets, liabilities, financial position and profit and loss of the Company as at 28 February 2023 as required by the Disclosure Guidance and Transparency Rule 4.2.4R;
- the Interim Report includes a fair review as required by Disclosure Guidance and Transparency Rule 4.2.7R, of important events that have occurred during the six months to 28 February 2023 and their impact on the condensed set of Financial Statements, and a description of the principal and emerging risks for the remaining six months of the financial year; and
- the Interim Report includes a fair review of the information concerning related party transactions as required by Disclosure Guidance and Transparency Rule 4.2.8R.

The Interim Report has not been reviewed or audited by the Company's Auditors.

The Interim Report for the six months ended 28 February 2023 was approved by the Board and the above Responsibilities Statement has been signed on its behalf by:

**KATE CORNISH-BOWDEN** | Chair

2 May 2023

## STATEMENT OF COMPREHENSIVE INCOME

Notes	(Unaudited) For the six months ended 28 February 2023			(Unaudited) For the six months ended 28 February 2022			(Audited) For the year ended 31 August 2022			
	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	Revenue £'000	Capital £'000	Total £'000	
Gains/(losses) on investments held at fair value	—	18,294	18,294	—	(46,452)	(46,452)	—	(14,696)	(14,696)	
Exchange gains/(losses) on currency balances	—	564	564	—	(609)	(609)	—	(4,378)	(4,378)	
Income	2	447	—	447	647	—	647	1,113	—	1,113
<b>Expenses</b>										
Management fee	(873)	—	(873)	(1,289)	—	(1,289)	(2,009)	—	(2,009)	
Performance fee	—	(199)	(199)	—	—	—	—	(471)	(471)	
Administrative expenses	(659)	—	(659)	(575)	—	(575)	(1,218)	—	(1,218)	
<b>Profit/(loss) before finance costs and tax</b>	<b>(1,085)</b>	<b>18,659</b>	<b>17,574</b>	<b>(1,217)</b>	<b>(47,061)</b>	<b>(48,278)</b>	<b>(2,114)</b>	<b>(19,545)</b>	<b>(21,659)</b>	
Interest payable	(560)	—	(560)	(257)	—	(257)	(663)	—	(663)	
<b>Profit/(loss) on ordinary activities before tax</b>	<b>(1,645)</b>	<b>18,659</b>	<b>17,014</b>	<b>(1,474)</b>	<b>(47,061)</b>	<b>(48,535)</b>	<b>(2,777)</b>	<b>(19,545)</b>	<b>(22,322)</b>	
Taxation	(54)	—	(54)	(97)	—	(97)	(151)	—	(151)	
<b>Profit/(loss) for the year attributable to Shareholders</b>	<b>(1,699)</b>	<b>18,659</b>	<b>16,960</b>	<b>(1,571)</b>	<b>(47,061)</b>	<b>(48,632)</b>	<b>(2,928)</b>	<b>(19,545)</b>	<b>(22,473)</b>	
Basic and diluted earnings/(loss) per Ordinary share	3	(4.17)p	45.74p	41.57p	(3.81)p	(114.14)p	(117.95)p	(7.13)p	(47.59)p	(54.72)p

All revenue and capital items in the above statement derive from continuing operations. The total column of this statement represents the Company's Statement of Comprehensive Income, prepared in accordance with IFRSs.

The Company does not have any other comprehensive income and hence the net profit for the year, as disclosed above, is the same as the Company's total comprehensive income.

The revenue and capital columns are supplementary and are prepared under guidance published by the AIC.

The notes on pages 22 to 25 form part of these Financial Statements.

28 February 2023

## STATEMENT OF CHANGES IN EQUITY

For the six months ended 28 February 2023 (Unaudited)	Called up share capital £'000	Share premium account £'000	Capital redemption reserve £'000	Capital reserves £'000	Revenue reserve £'000	Total £'000
Balance at 1 September 2022	10,346	29,873	31,482	259,849	(46,661)	284,889
<b>Total Comprehensive Income:</b>						
Profit/(loss) for the period	—	—	—	18,659	(1,699)	16,960
<b>Transactions with owners, recorded directly to equity:</b>						
Dividends paid in the period	—	—	—	(5,707)	—	(5,707)
Ordinary shares bought back into treasury	—	—	—	(646)	—	(646)
Balance at 28 February 2023	10,346	29,873	31,482	272,155	(48,360)	295,496

For the six months ended 28 February 2022 (Unaudited)	Called up share capital £'000	Share premium account £'000	Capital redemption reserve £'000	Capital reserves £'000	Revenue reserve £'000	Total £'000
Balance at 1 September 2021	10,346	29,873	31,482	295,807	(43,733)	323,775
<b>Total Comprehensive Income:</b>						
Loss for the period	—	—	—	(47,061)	(1,571)	(48,632)
<b>Transactions with owners, recorded directly to equity:</b>						
Dividends paid in the period	—	—	—	(6,464)	—	(6,464)
Ordinary shares bought back into treasury	—	—	—	(1,639)	—	(1,639)
Balance at 28 February 2022	10,346	29,873	31,482	240,643	(45,304)	267,040

For the year ended 31 August 2022 (Audited)	Called up share capital £'000	Share premium account £'000	Capital redemption reserve £'000	Capital reserves £'000	Revenue reserve £'000	Total £'000
Balance at 1 September 2021	10,346	29,873	31,482	295,807	(43,733)	323,775
<b>Total Comprehensive Income:</b>						
Loss for the year	—	—	—	(19,545)	(2,928)	(22,473)
<b>Transactions with owners, recorded directly to equity:</b>						
Dividends paid in the year	—	—	—	(12,879)	—	(12,879)
Ordinary shares bought back into treasury	—	—	—	(3,534)	—	(3,534)
Balance at 31 August 2022	10,346	29,873	31,482	259,849	(46,661)	284,889

The notes on pages 22 to 25 form part of these Financial Statements.

**BALANCE SHEET** | as at 28 February 2023

Notes	(Unaudited) At 28 February 2023 £'000	(Unaudited) At 28 February 2022 £'000	(Audited) At 31 August 2022 £'000
<b>Non-current assets</b>			
Investments held at fair value through profit or loss	<b>321,668</b>	312,388	313,429
	<b>321,668</b>	312,388	313,429
<b>Current assets</b>			
Receivables	<b>9,525</b>	188	13,487
Cash and cash equivalents	–	–	–
	<b>9,525</b>	188	13,487
<b>Total assets</b>	<b>331,193</b>	312,576	326,916
<b>Current liabilities</b>			
Borrowings	<b>(24,193)</b>	(45,140)	(39,976)
Payables	<b>(11,504)</b>	(396)	(2,051)
	<b>(35,697)</b>	(45,536)	(42,027)
<b>Net assets</b>	<b>295,496</b>	267,040	284,889
<b>Equity attributable to equity holders</b>			
Called up share capital	<b>10,346</b>	10,346	10,346
Share premium account	<b>29,873</b>	29,873	29,873
Capital redemption reserve	<b>31,482</b>	31,482	31,482
Capital reserves	<b>272,155</b>	240,643	259,849
Revenue reserve	<b>(48,360)</b>	(45,304)	(46,661)
<b>Total equity</b>	<b>295,496</b>	267,040	284,889
NAV per Ordinary share	<b>6</b>	724.88p	648.82p
		697.18p	

The notes on pages 22 to 25 form part of these Financial Statements.

International Biotechnology Trust plc  
Company Number 2892872

## CASH FLOW STATEMENT

	(Unaudited) For the six months ended 28 February 2023 £'000	(Unaudited) For the six months ended 28 February 2022 £'000	(Audited) For the year ended 31 August 2022 £'000
<b>Cash flows from operating activities</b>			
Profit/(loss) on ordinary activities before tax	17,014	(48,535)	(22,322)
Adjustments for:			
Decrease in investments	5,378	32,948	19,009
(Gains)/losses on foreign exchange	(564)	—	4,375
(Increase)/decrease in receivables	(99)	754	(33)
(Decrease)/increase in payables	(112)	(1,795)	261
Taxation	(45)	(97)	(166)
<b>Net cash flows generated from/(used in) operating activities</b>	<b>21,572</b>	<b>(16,725)</b>	<b>1,124</b>
<b>Cash flows from financing activities</b>			
Buyback of Ordinary shares into treasury	(646)	(1,639)	(3,534)
Dividends paid	(5,707)	(6,464)	(12,879)
<b>Net cash used in financing activities</b>	<b>(6,353)</b>	<b>(8,103)</b>	<b>(16,413)</b>
Effect of foreign exchange rates	564	—	(4,375)
<b>Net generated from/(used in) in cash and cash equivalents</b>	<b>15,783</b>	<b>(24,828)</b>	<b>(19,664)</b>
Cash and cash equivalents at 1 March	(39,976)	(20,312)	(20,312)
Cash and cash equivalents at 28 February	<b>(24,193)</b>	<b>(45,140)</b>	<b>(39,976)</b>

The notes on pages 22 to 25 form part of these Financial Statements.

## NOTES TO THE FINANCIAL STATEMENTS | as at 28 February 2023

### 1. ACCOUNTING POLICIES

The Financial Statements have been prepared on a going concern basis, in accordance with International Accounting Standard 34 *Interim Financial Reporting* and the accounting policies set out in the Annual Report of the Company for the year ended 31 August 2022. Where presentational guidance set out in the Statement of Recommended Practice (the SORP) for investment trusts issued by the Association of Investment Companies in October 2019 is inconsistent with the requirements of IFRS, the Financial Statements have been prepared on a basis compliant with the recommendations of the SORP.

The interim information for each of the six month periods ended 28 February 2023 and 28 February 2022 comprises non-statutory accounts within the meaning of Sections 434 - 436 of the Companies Act 2006 (the Act). The financial information for the year ended 31 August 2022 has been extracted from published accounts that have been delivered to the Registrar of Companies and on which the report of the auditors was unqualified, did not draw attention to any matters by way of emphasis and did not contain a statement under section 498(2) or (3) of the Act.

The Company has reviewed the guidance issued by the Financial Reporting Council (FRC) in order to determine whether the going concern basis should be used in preparing the Financial Statements for the six months ended 28 February 2023. The Directors have reviewed the likely operational costs and cashflows for the Company for the 12 months from the date of this Half Yearly Report and are of the opinion that the Company has adequate resources to continue in operational existence for the foreseeable future. The Directors believe that it is appropriate to adopt the going concern basis in the preparation of the Financial Statements as there are no material uncertainties related to events or conditions that may cast significant doubt about the Company's ability to continue as a going concern.

The Company's principal and emerging risks remained unchanged to those described in the Annual Report for the year ended 31 August 2022. These include strategic/performance risk, political risk, investment related risks, operational risks and tax, legal and regulatory risks. These risks, and the way in which they are managed, are described in more detail under the heading *Principal and emerging risks* within the Strategic Report in the Company's Annual Report for the year ended 31 August 2022.

### 2. INCOME

	(Unaudited) For the six months ended 28 February 2023 £'000	(Unaudited) For the six months ended 28 February 2022 £'000	(Audited) For the year ended 31 August 2022 £'000
<b>Income from investments held at fair value through profit or loss:</b>			
Unfranked dividends	360	647	1,113
Franked dividends	80	—	—
<b>Other income:</b>			
Bank interest	7	—	—
	<b>447</b>	<b>647</b>	<b>1,113</b>

## NOTES TO THE FINANCIAL STATEMENTS | continued

### 3. NET (LOSSES)/EARNINGS PER ORDINARY SHARE

	(Unaudited) For the six months ended 28 February 2023 £'000	(Unaudited) For the six months ended 28 February 2022 £'000	(Audited) For the year ended 31 August 2022 £'000
Net revenue loss (£'000)	(1,699)	(1,571)	(2,928)
Net capital profit/(loss) (£'000)	18,659	(47,061)	(19,545)
	<b>16,960</b>	<b>(48,632)</b>	<b>(22,473)</b>
<b>Weighted average number of Ordinary shares in issue*</b>	<b>40,794,704</b>	41,231,966	41,072,164
	Pence	Pence	Pence
<b>Revenue loss per Ordinary share</b>	<b>(4.17)p</b>	(3.81)p	(7.13)p
<b>Capital profit/(loss) per Ordinary share</b>	<b>45.74p</b>	(114.14)p	(47.59)p
<b>Total earnings/(losses) per Ordinary share</b>	<b>41.57p</b>	(117.95)p	(54.72)p

\*Excludes those held in treasury (28 February 2023: 618,988; 28 February 2022: 225,970; 31 August 2022: 520,808).

### 4. INVESTMENTS HELD AT FAIR VALUE THROUGH PROFIT OR LOSS

The Company's portfolio of investments, comprising investments in companies and any derivatives, are carried in the balance sheet at fair value. Other financial instruments held by the Company comprise amounts due to or from brokers, dividends and interest receivable, accruals, cash and drawings on the credit facility. For these instruments, the balance sheet amount is a reasonable approximation of fair value. The recognition and measurement policies for financial instruments measured at fair value have not changed from those set out in the statutory accounts of the Company for the year ended 31 August 2022.

The investments in the Company's portfolio are categorised into a hierarchy comprising the following three levels:

Level 1 - valued using quoted prices in active markets.

Level 2 - valued by reference to valuation techniques using observable inputs other than quoted market prices included within Level 1.

Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data.

Categorisation within the hierarchy has been determined on the basis of the lowest level input that is significant to the fair value measurement of the relevant asset.

At 28 February 2023, the Company's investment portfolio was categorised as follows:

	(Unaudited) At 28 February 2023 £'000	(Unaudited) At 28 February 2022 £'000	(Audited) At 31 August 2022 £'000
Level 1	286,934	284,107	285,471
Level 2	—	—	—
Level 3	34,734	28,281	27,958
<b>Total</b>	<b>321,668</b>	<b>312,388</b>	<b>313,429</b>

There have been no transfers between Level 1, 2 or 3 during the period (period ended 28 February 2022 and year ended 31 August 2022: nil).

## NOTES TO THE FINANCIAL STATEMENTS | continued

### 5. CAPITAL RESERVES

The capital reserve account comprises both realised gains on investments sold and unrealised gains and losses on investments held, which are analysed as follows:

	(Unaudited) At 28 February 2023 £'000	(Unaudited) At 28 February 2022 £'000	(Audited) At 31 August 2022 £'000
Capital reserve – on investments sold	273,192	273,449	265,122
Capital reserve – on investments held	(1,037)	(32,806)	(5,273)
	<b>272,155</b>	240,643	259,849

### 6. NET ASSET VALUE PER ORDINARY SHARE

	(Unaudited) At 28 February 2023	(Unaudited) At 28 February 2022	(Audited) At 31 August 2022
Net assets attributable to Ordinary Shareholders (£'000)	295,496	267,040	284,889
Ordinary shares in issue at end of period*	40,764,829	41,157,847	40,863,009
NAV per Ordinary share (pence)	<b>724.88</b>	648.82	697.18

\*Excludes those held in treasury (28 February 2023: 618,988; 28 February 2022: 225,970; 31 August 2022: 520,808).

### 7. RELATED PARTY TRANSACTIONS

There have been no related party transactions that have materially affected the financial position or the performance of the Company during the six month period to 28 February 2023.

#### a) Transactions with the Investment Manager

Details of the management fee arrangement are given in the Directors' Report on page 35 of the Annual Report for the year ended 31 August 2022. Following the investment into the SV Fund VI in October 2016 and SV BCOF in December 2021, a portion of the management fee has been paid via fees due on these investments, with the remaining fees charged directly to the Company. The amounts paid can be seen in the table below and continue to total 0.9% of NAV.

	(Unaudited) At 28 February 2023 £'000	(Unaudited) At 28 February 2022 £'000	(Audited) At 31 August 2022 £'000
<b>Fees paid to the Investment Manager:</b>			
Management fee paid through unquoted funds	427,556	92,353	623,361
Management fee paid by the Company directly to the Fund Manager	872,740	1,288,775	2,009,347
<b>Total</b>	<b>1,300,296</b>	1,381,128	2,632,708

A performance fee of £199,000 has been accrued as at 28 February 2023 (28 February 2022: £nil; 31 August 2022: £471,000).



## NOTES TO THE FINANCIAL STATEMENTS | continued


### b) Transactions with Key Management Personnel

The Directors of the Company are key management personnel. The total remuneration payable to Directors in respect of the six months ended 28 February 2023 was £84,000 (28 February 2022: £80,000), of which £nil (28 February 2022: £nil) was outstanding at the period end.

### 8. EVENTS AFTER THE REPORTING PERIOD

After the period end and up to 28 April 2023, 176,738 Ordinary shares were brought back to be held in treasury. Following these buybacks, the total number of shares in issue was 41,383,817 of which 795,726 were held in treasury.

The Directors have evaluated the period since the interim date and have not noted any other significant events after the end of the reporting period to the date of this Report requiring disclosure.



## QUOTED INVESTMENTS

QUOTED INVESTMENTS RANKED BY % OF NAV			As at 28 February 2023		As at 31 August 2022		
Investment	Therapeutic area	Geographic location	£'000	% of NAV	£'000	% of NAV	
1	Seagen	Oncology	United States	<b>29,680</b>	<b>10.0%</b>	22,036	7.7%
2	Amgen	Oncology	United States	<b>17,456</b>	<b>5.9%</b>	3,352	1.2%
3	Harmony Biosciences	Rare diseases	United States	<b>14,695</b>	<b>5.0%</b>	9,981	3.5%
4	Supernus Pharmaceuticals	Central nervous system	United States	<b>13,149</b>	<b>4.4%</b>	8,752	3.1%
5	Alkermes	Central nervous system	Europe	<b>13,088</b>	<b>4.4%</b>	6,669	2.3%
6	Uniqure	Haematology	Europe	<b>12,588</b>	<b>4.3%</b>	7,611	2.7%
7	Incyte Genomics	Oncology	United States	<b>12,013</b>	<b>4.1%</b>	14,644	5.1%
8	Intra Cellular Therapies	Central nervous system	United States	<b>10,443</b>	<b>3.5%</b>	7,639	2.7%
9	Mirati Therapeutics	Oncology	United States	<b>9,239</b>	<b>3.1%</b>	9,461	3.3%
10	Exelixis	Oncology	United States	<b>7,652</b>	<b>2.6%</b>	8,278	2.9%
11	Illumina Inc	Tools & Diagnostics	United States	<b>7,651</b>	<b>2.6%</b>	4,332	1.5%
12	Regeneron Pharmaceuticals	Ophthalmology	United States	<b>7,029</b>	<b>2.4%</b>	11,830	4.2%
13	Dyne Therapeutics	Rare diseases	United States	<b>6,815</b>	<b>2.3%</b>	2,939	1.0%
14	Ultragenyx Pharmaceutical	Rare diseases	United States	<b>6,385</b>	<b>2.2%</b>	7,132	2.5%
15	Vera Therapeutics	Auto-immune	United States	<b>6,134</b>	<b>2.1%</b>	5,144	1.8%
16	Chinook Therapeutics	Auto-immune	United States	<b>6,129</b>	<b>2.1%</b>	6,073	2.1%
17	Alnylam Pharmaceuticals	Rare diseases	United States	<b>6,004</b>	<b>2.0%</b>	6,745	2.4%
18	Sanofi	Other	Europe	<b>5,553</b>	<b>1.9%</b>	5,060	1.8%
19	BioMarin Pharmaceutical	Rare diseases	United States	<b>4,825</b>	<b>1.6%</b>	4,496	1.6%
20	Swedish Orphan Biovitrum	Haematology	Europe	<b>4,768</b>	<b>1.6%</b>	1,443	0.5%
21	Biogen Inc	Central nervous system	United States	<b>4,765</b>	<b>1.6%</b>	7,637	2.7%
22	Aurinia Pharmaceuticals	Auto-immune	United States	<b>4,316</b>	<b>1.5%</b>	3,623	1.3%
23	BeiGene	Oncology	United States	<b>4,212</b>	<b>1.4%</b>	2,316	0.8%
24	Krystal Biotech	Rare diseases	United States	<b>4,126</b>	<b>1.4%</b>	2,711	1.0%
25	Gilead Sciences	Infectious diseases	United States	<b>3,829</b>	<b>1.3%</b>	11,387	4.0%
26	Acadia Pharmaceuticals	Central nervous system	United States	<b>3,691</b>	<b>1.2%</b>	—	—
27	Argen X	Rare diseases	Europe	<b>3,686</b>	<b>1.2%</b>	2,517	0.9%
28	AstraZeneca	Oncology	United Kingdom	<b>3,498</b>	<b>1.2%</b>	—	—
29	PTC Therapeutics	Rare diseases	United States	<b>3,350</b>	<b>1.1%</b>	901	0.3%
30	Erasca	Oncology	United States	<b>3,067</b>	<b>1.0%</b>	—	—
31	United Therapeutics	Rare diseases	United States	<b>3,045</b>	<b>1.0%</b>	2,922	1.0%
32	Genmab	Oncology	United States	<b>2,728</b>	<b>0.9%</b>	—	—
33	Ascendis Pharma	Rare diseases	United States	<b>2,696</b>	<b>0.9%</b>	2,262	0.8%
34	Travere Therapeutics	Rare diseases	United States	<b>2,580</b>	<b>0.9%</b>	7,038	2.5%

28 February 2023

## QUOTED INVESTMENTS | continued

QUOTED INVESTMENTS RANKED BY % OF NAV			As at 28 February 2023		As at 31 August 2022		
Investment	Therapeutic area	Geographic location	£'000	% of NAV	£'000	% of NAV	
35	Revanche Therapeutics	Other	United States	2,577	0.9%	—	—
36	Zai Lab Ltd	Oncology	United States	2,420	0.8%	3,121	1.1%
37	Caribou Biosciences Inc	Oncology	United States	2,296	0.8%	2,188	0.8%
38	Horizon Therapeutics	Rare diseases	United States	2,259	0.8%	23,151	8.1%
39	Novocure	Oncology	Europe	2,032	0.7%	2,254	0.8%
40	Jazz Pharmaceuticals	Rare diseases	Europe	1,994	0.7%	2,295	0.8%
41	Guardant Health	Tools & diagnostics	United States	1,899	0.6%	3,193	1.1%
42	Karuna Therapeutics	Central nervous system	United States	1,810	0.6%	—	—
43	Apellis Pharmaceuticals	Rare diseases	United States	1,712	0.6%	—	—
44	Legend Biotech	Oncology	United States	1,450	0.5%	1,516	0.5%
45	CRISPR Therapeutics	Rare diseases	United States	1,393	0.5%	1,910	0.7%
46	Mirum Pharmaceuticals	Rare diseases	United States	1,308	0.4%	—	—
47	Ionis Pharmaceuticals	Rare diseases	United States	1,275	0.4%	—	—
48	I Mab (ADR)	Oncology	United States	1,103	0.4%	2,663	0.9%
49	Novavax Inc	Infectious diseases	United States	1,009	0.3%	3,762	1.3%
50	Adicet Bio Inc	Oncology	United States	1,007	0.3%	1,881	0.7%
51	Rocket Pharmaceuticals	Rare diseases	United States	997	0.3%	833	0.3%
52	Hutchmed China (ADR)	Oncology	United States	930	0.3%	751	0.3%
53	Denali Therapeutics	Central nervous system	United States	852	0.3%	902	0.3%
54	Xenon Pharmaceuticals	Central nervous system	United States	828	0.3%	851	0.3%
55	Intellia Therapeutics	Rare diseases	United States	796	0.3%	1,238	0.4%
56	Beam Therapeutics	Oncology	United States	781	0.3%	1,102	0.4%
57	Insmed Inc	Rare diseases	United States	674	0.2%	848	0.3%
58	Ironwood Pharmaceuticals	Other	United States	558	0.2%	555	0.2%
59	Ventyx Biosciences	Rare diseases	United States	535	0.2%	—	—
60	Arvinas	Oncology	United States	430	0.1%	—	—
61	Biocryst Pharmaceuticals	Rare diseases	United States	416	0.1%	680	0.2%
62	Iovance Biotherapeutics	Oncology	United States	337	0.1%	515	0.2%
63	Ideaya Biosciences	Oncology	United States	277	0.1%	918	0.3%
64	Black Diamond Therapeutics	Oncology	United States	64	—	121	—
65	Relmada Therapeutics	Central nervous system	United States	30	—	251	0.1%
Investments no longer held in the portfolio as at 28 February 2023			—	—	31,041	10.9%	
<b>Total quoted investments</b>			<b>286,934</b>	<b>96.8%</b>	<b>285,471</b>	<b>100.2%</b>	

## UNQUOTED INVESTMENTS

### INVESTMENTS HELD THROUGH A VENTURE FUND

Investment	Sector classification	Geographic location	As at 28 February 2023		As at 31 August 2022		
			£'000	% of NAV	£'000	% of NAV	
1	SV Fund VI	Venture Fund	United States	<b>16,993</b>	<b>5.8%</b>	18,866	6.6%
2	SV BCOF	Venture Fund	United Kingdom	<b>12,273</b>	<b>4.2%</b>	3,411	1.2%
<b>Total investments held through a venture fund</b>				<b>29,266</b>	<b>10.0%</b>	<b>22,277</b>	<b>7.8%</b>

### EXITED INVESTMENTS WITH CONTINGENT MILESTONES

Exited unquoted companies for which the Company retains rights to receive future contingent performance-based payments are shown below.

Investment	Therapeutic area	Geographic location	As at 28 February 2023		As at 31 August 2022		
			£'000	% of NAV	£'000	% of NAV	
1	Ikano Therapeutics	Auto-immune	United States	<b>4,056</b>	<b>1.4%</b>	4,330	1.5%
2	Archemix	Oncology	United States	<b>598</b>	<b>0.2%</b>	284	0.1%
3	Convergence	Auto-immune	United States	<b>335</b>	<b>0.1%</b>	349	0.1%
4	NCP Holdings	Healthcare services	United States	<b>46</b>	—	88	—
5	Spinal Kinetics	Medical Devices	United States	<b>2</b>	—	289	0.1%
<b>Total exited investments with contingent milestones</b>				<b>5,037</b>	<b>1.7%</b>	<b>5,340</b>	<b>1.8%</b>

### DIRECTLY-HELD UNQUOTED INVESTMENTS

Directly-held unquoted investments held by the Company are shown below:

Investment	Therapeutic area	Geographic location	As at 28 February 2023		As at 31 August 2022		
			£'000	% of NAV	£'000	% of NAV	
1	Autifony Therapeutics	Infectious diseases	United Kingdom	<b>341</b>	<b>0.1%</b>	341	0.1%
2	Karus Therapeutics	Oncology	United Kingdom	<b>90</b>	—	—	—
<b>Total directly-held unquoted investments</b>				<b>431</b>	<b>0.1%</b>	<b>341</b>	<b>0.1%</b>

SUMMARY OF UNQUOTED INVESTMENTS	As at 28 February 2023		As at 31 August 2022	
	£'000	% of NAV	£'000	% of NAV
<b>Investments held through a venture fund</b>	<b>29,266</b>	<b>10.0%</b>	<b>22,277</b>	<b>7.8%</b>
<b>Total exited investments with contingent milestones</b>	<b>5,037</b>	<b>1.7%</b>	<b>5,340</b>	<b>1.8%</b>
<b>Total directly-held unquoted investments</b>	<b>431</b>	<b>0.1%</b>	<b>341</b>	<b>0.1%</b>
<b>Total unquoted investments</b>	<b>34,734</b>	<b>11.8%</b>	<b>27,958</b>	<b>9.7%</b>

## ALTERNATIVE PERFORMANCE MEASURES (APMs)

The Board uses the following APMs to review the performance of the Company (listed in alphabetical order):

### Discount/Premium

The Company's share price is not always the same as the NAV per share. If the share price is lower than the NAV per share, the shares are said to be trading 'at a discount'. If the share price is above the NAV per share, the shares are said to be trading 'at a premium'. The Board's objective is to keep the discount within a defined range and actively monitors it to allow it to take the correcting action of conducting share buybacks when the discount widens beyond that range.

		As at 28 February 2023	As at 28 February 2022	As at 31 August 2022
NAV per share (pence)	a	724.9	648.8	697.2
Share price (pence)	b	690.0	636.0	651.5
<b>Discount</b>	<b>(b ÷ a) - 1</b>	<b>(4.8)%</b>	<b>(2.0)%</b>	<b>(6.6)%</b>

### Gearing

Gearing for this purpose is defined as borrowings used for investment purposes, less cash, expressed as a percentage of net assets. The Company has authority to use gearing to a maximum of 30% of NAV and this is monitored daily to ensure this level is not exceeded.

		As at 28 February 2023	As at 28 February 2022	As at 31 August 2022
Borrowings used for investment purposes including cash (£'000)	a	24,193	45,140	39,976
Net assets (£'000)	b	295,496	267,040	284,889
<b>Gearing</b>	<b>a ÷ b</b>	<b>8.2%</b>	<b>16.9%</b>	<b>14.0%</b>

### Ongoing charges

Ongoing charges are calculated in accordance with the AIC's recommended methodology using the charges for the current year and the average NAV during the year. This calculation allows a comparison to be made between the costs of the Company and external investment companies and is a key metric used by the Board to ensure it remains competitive.

		Six months ended 28 February 2023 £'000	Six months ended 28 February 2022 £'000	Year ended 31 August 2022 £'000
Management fee - Company (£'000)		873	1,289	2,009
Management fee - unquoted funds (£'000)		428	92	623
Administrative expenses (£'000)		659	575	1,218
<b>Total ongoing expenses (£'000)</b>		<b>1,960</b>	<b>1,956</b>	<b>3,850</b>
<b>Total ongoing expenses annualised (£'000)</b>	a	<b>3,952</b>	<b>3,912</b>	<b>3,850</b>
<b>Average daily NAV (£'000)</b>	b	<b>291,810</b>	<b>284,067</b>	<b>290,719</b>
<b>Ongoing charges (expressed as a percentage)</b>	<b>a ÷ b</b>	<b>1.4%</b>	<b>1.4%</b>	<b>1.3%</b>

## APMs | continued

### Total return

The total return is the return to Shareholders after reinvesting the net dividend on the date that the share price goes ex-dividend. Total return is the primary measurement used by the Board to assess Company performance against the benchmark and its competitors on a consistent basis.

#### a) NAV total return

		Six months ended 28 February 2023	Six months ended 28 February 2022	Year ended 31 August 2022
Opening NAV per share (pence)	a	697.2	782.4	782.4
Closing NAV per share (pence)	b	724.9	648.8	697.2
Dividend adjustment factor*	c	1.020	1.0242	1.0450
<b>Adjusted closing NAV per share</b>	d = b x c	<b>739.4</b>	664.5	728.6
<b>Total return</b>	(d ÷ a) - 1	<b>6.1%</b>	-15.1%	-6.9%

\* The dividend adjustment factor is calculated on the assumption that the dividends paid by the Company during the year were reinvested into shares of the Company at the cum income NAV per share/share price, as appropriate, at the ex-dividend date.

NAV total return is analysed further into its components and sub-components, namely quoted portfolio total return, unquoted funds total return and directly-held unquoted portfolio total return, as discussed in the Chair's Statement and Fund Manager's Review. The calculations for these components of total return take into account individual investment's pricing movements, acquisitions and disposals, the dividend adjustment factor, fees and administration expenses incurred by the Company.

#### b) Share price total return

		Six months ended 28 February 2023	Six months ended 28 February 2022	Year ended 31 August 2022
Opening price per share (pence)	a	651.5	729.5	729.5
Closing price per share (pence)	b	690.0	636.0	651.5
Dividend adjustment factor*	c	1.020	1.0247	1.0482
<b>Adjusted closing price per share (pence)</b>	d = b x c	<b>703.8</b>	651.7	682.9
<b>Total return</b>	(d ÷ a) - 1	<b>8.0%</b>	-10.7%	-6.4%

\* The dividend adjustment factor is calculated on the assumption that the dividends paid by the Company during the year were reinvested into shares of the Company at the cum income NAV per share/share price, as appropriate, at the ex-dividend date.

## GLOSSARY OF TERMS

**Administrator** – the administrator is The Northern Trust Company to which the Company has delegated certain trade processing, valuation and middle office tasks and systems.

**AIC** – Association of Investment Companies, the trade body for investment companies.

**AIFM** – Alternative Investment Fund Manager – SV Health Managers LLP.

**AIFMD** – Alternative Investment Fund Managers Directive – Issued by the European Parliament in 2012 and 2013, the Directive requires that all investment vehicles (AIFs) in the European Union, including investment trusts, appoint a Depositary and an Alternative Investment Fund Manager (AIFM). The Board remains responsible, however, for all aspects of the Company's strategy, operations and compliance with regulations.

**APM(s)** – Alternative Performance Measures (please refer to pages 29 and 30).

**Benchmark** – the benchmark is the NASDAQ Biotechnology Index (NBI) (total return in sterling with dividends reinvested).

**Company** – International Biotechnology Trust plc or IBT.

**Custodian** – the Custodian is Northern Trust Investor Services Limited. The Custodian is a financial institution responsible for safeguarding the securities and cash assets of the Company, as well as the income arising therefrom, through provision of custodial, settlement and associated services.

**Depositary** – the Depositary is Northern Trust Investor Services Limited. Under AIFMD rules, the Company must have a Depositary whose duties in respect of investments and cash include safekeeping; verification of ownership and valuation; and cash monitoring. Under the AIFMD rules, the Depositary has strict liability for the loss of the Company's financial assets in respect of which it has safekeeping duties.

**Discount/Premium** – the share price of an investment trust is derived from buyers and sellers trading their shares on the London Stock Exchange and is not always the same as the NAV per share. If the share price is lower than the NAV per share, the shares are said to be trading 'at a discount'. If the share price is above the NAV per share, the shares are said to be trading 'at a premium'.

**Distributable reserves** – reserves distributable by way of dividend or for the purpose of buying back Ordinary share capital.

**Fund Manager and Alternative Investment Fund Manager (AIFM)** – SV Health Managers LLP. The responsibilities and remuneration of the Fund Manager are set out in the Directors' Report and note 4 of the 2022 Annual Report.

**Independent Auditors** – PricewaterhouseCoopers LLP.

**Initial public offering (IPO)** – an initial public offering (IPO) refers to the process of offering shares of a private company to the public in a new stock issuance for the first time. An IPO allows a company to raise equity capital from public investors.

**Joint Lead Investment Managers** – Ailsa Craig and Marek Poszepczynski, employees of the Fund Manager with overall management responsibility for the total portfolio.

**Management fee** – the Fund Manager is entitled to a management fee payable monthly at the rate of 0.9% per annum of the Company's NAV.

**Market capitalisation** – the stock market quoted price of the Company's shares, multiplied by the number of shares in issue. If the Company's shares trade at a discount to NAV, the market capitalisation will be lower than the NAV.

**Net Asset Value (NAV)** – the assets less the liabilities of the Company, as set out in the Statement of Financial Position, all valued in accordance with the Company's accounting policies as described in note 1 of the 2022 Annual Report.

**Non-executive Director** – a Director who has a letter of appointment, rather than a contract of employment, with the Company. The Company does not have any executive Directors.

**Ongoing charges** – ongoing charges are all operating costs expected to be regularly incurred and that are payable by the Company. Ongoing charges are calculated in accordance with the Association of Investment Companies (the AIC) guidance, based on total expenses excluding finance costs and performance fee and expressed as a percentage of average daily net assets. The ratio including performance fee has also been provided, in line with the AIC recommendations. Research costs under MiFID II borne by the Company is included in the ongoing charges calculation.

## GLOSSARY OF TERMS | continued

**Performance fee** – the Fund Manager is entitled to a performance fee which is calculated as follows:

- The fee on the quoted portfolio is 10% of relative outperformance above the sterling-adjusted NBI plus a 0.5% hurdle.
- The fee on the unquoted pool, excluding the investment in unquoted funds, is 20% of net realised gains, taking into account any unrealised losses but not unrealised gains.

The payment of the performance fee is subject to the following limits:

- The maximum performance fee in any one year is 2% of average net assets; and
- Any underperformance of the quoted portfolio against the benchmark is carried forward for the current financial period plus two succeeding periods. Performance fees in excess of the performance fee cap are carried forward for the current financial period plus two succeeding periods and being offset against any subsequent underperformance before being paid out.

**SV BCOF** – SV Biotech Crossover Opportunities Fund LP.

**Total return** – the total return is the return to Shareholders after reinvesting the net dividend on the date that the share price goes ex-dividend.

**UK Corporate Governance Code (UK Code)** – the standards of good practice in relation to board leadership and effectiveness, remuneration, accountability and relations with Shareholders that all companies with a Premium Listing on the London Stock Exchange are required to report on in their annual report and accounts.





## COMPANY SUMMARY AND SHAREHOLDER INFORMATION

### Company Status

The Company was established in 1994 as an independent investment trust whose shares are listed on the London Stock Exchange (Ordinary shares: ISIN No: GB0004559349; EPIC Code: IBT). The Company is registered in England and Wales with a company number of 2892872.

### Life of the Company

The Company's Articles of Association provide for Directors to put forward a proposal for the continuation of the Company at the Company's AGM at two-yearly intervals. Accordingly, a proposal will be put forward at the Company's AGM to be held in December 2023.

### Share Price and NAV Information

The Company releases its NAV per share to the market on a daily basis.

### Association of Investment Companies

The Company is a member of the Association of Investment Companies (the AIC). Further information on the AIC can be found at its website, [www.theaic.co.uk](http://www.theaic.co.uk).

### Financial Calendar

January	Payment of first interim dividend
3 May	Interim Results announced
August	Payment of second interim dividend
31 August	Year End
October	Annual Results announced
December	Annual General Meeting

### Shares in Issue

As at 28 April 2023, the Company had 41,383,817 Ordinary shares of 25p each in issue which included 795,726 Ordinary shares of 25p each held in treasury.

### Website

The Company's website is located at [www.ibtplc.com](http://www.ibtplc.com). The site provides share price and NAV information as well as details of the Board of Directors and SV Health Managers LLP, information on investee companies, monthly fact sheets, the latest published Annual and Half Yearly Financial Statements and access to recent market announcements.

## DIRECTORS AND ADVISERS

### DIRECTORS

Kate Cornish-Bowden (Chair)

Patrick Magee (Senior Independent Director)

Caroline Gulliver (Chair of the Audit Committee)

Gillian Elcock

Professor Patrick Maxwell

### ADVISERS

#### Fund Manager and AIFM

SV Health Managers LLP  
71 Kingsway, London, WC2B 6ST  
Telephone: 020 7421 7070

#### Company Secretary and IBT's Registered Office

Link Company Matters Limited  
6th Floor, 65 Gresham Street, London, England, EC2V 7NQ  
Telephone: +44 (0)20 7410 5971  
Email: [companymatters@linkgroup.co.uk](mailto:companymatters@linkgroup.co.uk)

#### Administrator

The Northern Trust Company  
50 Bank Street, London, E14 5NT

#### Custodian and Depository

Northern Trust Investor Services Limited  
50 Bank Street, London, E14 5NT

#### Independent Auditors

PricewaterhouseCoopers LLP  
Chartered Accountants and Statutory Auditors  
7 More London Riverside, London, SE1 2RT

#### Stockbroker

Numis Securities Limited  
The London Stock Exchange Building  
10 Paternoster Square, London, EC4M 7LT

#### Registrar

Equiniti Limited  
Aspect House, Spencer Road  
Lancing, West Sussex, BN99 6DA  
Shareholder Helpline: 0371 384 2624\*  
Overseas Helpline: +44 121 415 7047  
Website: [www.shareview.co.uk](http://www.shareview.co.uk)

*\*Lines are open from 8.30 am to 5.30 pm Monday to Friday  
(excluding public holidays in England and Wales).*







**INTERIM  
REPORT**  
28 February 2023

**SV Health Managers LLP**

71 Kingsway  
London WC2B 6ST  
Telephone: +44 (0)20 7421 7070  
Email: [IBT-IR@svhealthinvestors.com](mailto:IBT-IR@svhealthinvestors.com)

**Link Company Matters Limited**

6th Floor, 65 Gresham Street  
London EC2V 7NQ  
Telephone: +44 (0)20 7410 5971

For further information: [www.ibtplc.com](http://www.ibtplc.com)